Literature DB >> 20028336

Selective inhibition of beta-F1-ATPase mRNA translation in human tumours.

Imke M Willers1, Antonio Isidoro, Alvaro D Ortega, Pedro L Fernández, José M Cuezva.   

Abstract

Down-regulation of beta-F1-ATPase (the catalytic subunit of the mitochondrial H+-ATP synthase) is a hallmark of many human tumours. The expression level of beta-F1-ATPase provides a marker of the prognosis of cancer patients, as well as of the tumour response to chemotherapy. However, the mechanisms that participate in down-regulating its expression in human tumours remain unknown. In the present study, we have investigated the expression of beta-F1-ATPase mRNA (termed beta-mRNA) in breast, colon and lung adenocarcinomas and squamous carcinomas of the lung. Despite the down-regulation of the protein, tumour beta-mRNA levels remained either unchanged (breast and lung adenocarcinomas) or significantly increased (colon and squamous lung carcinomas) when compared with paired normal tissues, suggesting a specific translation-masking event for beta-mRNA in human cancer. Consistently, we show using cell-free translation assays that a large fraction (approximately 70%) of protein extracts derived from breast and lung adenocarcinomas specifically repress the translation of beta-mRNA. We show that the 3'UTR (3' untranslated region) of human beta-mRNA is a relevant cis-acting element required for efficient translation of the transcript. However, an RNA chimaera bearing the 3'UTR of human beta-mRNA does not recapitulate the inhibitory effect of tumour extracts on beta-mRNA translation. Overall, the findings of the present study support the hypothesis that down-regulation of the bioenergetic activity of mitochondria in human tumours is exerted by translation silencing of beta-mRNA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20028336     DOI: 10.1042/BJ20091570

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  15 in total

1.  Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype.

Authors:  Laura Sánchez-Cenizo; Laura Formentini; Marcos Aldea; Alvaro D Ortega; Paula García-Huerta; María Sánchez-Aragó; José M Cuezva
Journal:  J Biol Chem       Date:  2010-06-09       Impact factor: 5.157

Review 2.  Natural products and other inhibitors of F1FO ATP synthase.

Authors:  Bhargav A Patel; Terin L D'Amico; Brian S J Blagg
Journal:  Eur J Med Chem       Date:  2020-09-03       Impact factor: 6.514

3.  Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo.

Authors:  Joseph L Sottnik; Janet C Lori; Barbara J Rose; Douglas H Thamm
Journal:  Clin Exp Metastasis       Date:  2011-08-14       Impact factor: 5.150

Review 4.  Mitochondria-mediated energy adaption in cancer: the H(+)-ATP synthase-geared switch of metabolism in human tumors.

Authors:  María Sánchez-Aragó; Laura Formentini; José M Cuezva
Journal:  Antioxid Redox Signal       Date:  2012-09-24       Impact factor: 8.401

5.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Vincenzo Costigliola; Daniela Trog; Michael Braun; Manuel Debald; Walther Kuhn; Hans H Schild
Journal:  EPMA J       Date:  2013-02-19       Impact factor: 6.543

6.  Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites.

Authors:  My Wintzell; Elisabet Hjerpe; Elisabeth Åvall Lundqvist; Maria Shoshan
Journal:  BMC Cancer       Date:  2012-08-18       Impact factor: 4.430

7.  Reproducibility of an HPLC-ESI-MS/MS method for the measurement of stable-isotope enrichment of in vivo-labeled muscle ATP synthase beta subunit.

Authors:  Sarah Everman; Zhengping Yi; Paul Langlais; Lawrence J Mandarino; Moulun Luo; Christine Roberts; Christos S Katsanos
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

8.  cis-Expression QTL analysis of established colorectal cancer risk variants in colon tumors and adjacent normal tissue.

Authors:  Lenora W M Loo; Iona Cheng; Maarit Tiirikainen; Annette Lum-Jones; Ann Seifried; Lucas M Dunklee; James M Church; Robert Gryfe; Daniel J Weisenberger; Robert W Haile; Steven Gallinger; David J Duggan; Stephen N Thibodeau; Graham Casey; Loïc Le Marchand
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

9.  The genetic variant on chromosome 10p14 is associated with risk of colorectal cancer: results from a case-control study and a meta-analysis.

Authors:  Qin Qin; Li Liu; Rong Zhong; Li Zou; Jieyun Yin; Beibei Zhu; Beibei Cao; Wei Chen; Jigui Chen; Xiaorong Li; Tingting Li; Xuzai Lu; Jiao Lou; Juntao Ke; Sheng Wei; Xiaoping Miao; Shaofa Nie
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

10.  Expression, regulation and clinical relevance of the ATPase inhibitory factor 1 in human cancers.

Authors:  M Sánchez-Aragó; L Formentini; I Martínez-Reyes; J García-Bermudez; F Santacatterina; L Sánchez-Cenizo; I M Willers; M Aldea; L Nájera; A Juarránz; E C López; J Clofent; C Navarro; E Espinosa; J M Cuezva
Journal:  Oncogenesis       Date:  2013-04-22       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.